Shares of Tenet Healthcare (THC) saw modest movement this week, with investors keeping an eye on recent sector developments and assessing how these dynamics could impact the company’s performance as it heads into the next quarter.

See our latest analysis for Tenet Healthcare.

Tenet Healthcare’s shares have been on a strong run lately, surging almost 12% this week, which adds to an impressive year-to-date share price return of nearly 74%. This wave of momentum reflects a shift in investor sentiment as the company continues solid operational progress. It is supported by a one-year total shareholder return of 53% and a staggering 370% total return over three years, showing that long-term holders have seen substantial value creation as confidence has built around Tenet’s growth outlook and resilience.

Want to see how other healthcare stocks are performing? The easiest next step is to explore See the full list for free.

The question for investors is whether Tenet Healthcare’s impressive gains represent an undervalued opportunity, or if the anticipation of future growth is already fully reflected in the current share price.

Tenet Healthcare is trading at a price-to-earnings (P/E) ratio of 14.1x, which suggests strong value when compared to both peer companies and the wider healthcare industry. With the last close price at $217.42, the stock appears attractively priced relative to sector benchmarks.

The price-to-earnings ratio tells investors how much they are paying today for a dollar of earnings. In the healthcare sector, this ratio shows how the market values Tenet's current profitability and earnings potential versus its competitors.

The market may be underestimating Tenet’s recent operational achievements and growth trajectory. Considering the company’s robust multi-year shareholder returns and clear profitability, the current P/E ratio suggests the market is not fully pricing in long-term earnings power.

Compared to the US Healthcare industry average P/E of 22.7x and a calculated fair ratio of 24x, Tenet’s 14.1x ratio is significantly lower. This notable discount means the market could move closer to that fair valuation if confidence in future growth strengthens.

Explore the SWS fair ratio for Tenet Healthcare

Result: Price-to-Earnings of 14.1x (UNDERVALUED)

Still, potential headwinds such as slowing revenue growth or uncertainty in broader healthcare trends could quickly challenge the positive momentum seen in Tenet Healthcare’s stock.

Find out about the key risks to this Tenet Healthcare narrative.

While the P/E ratio suggests that Tenet Healthcare may be undervalued, our DCF model offers an even more compelling perspective. The SWS DCF model estimates fair value at $386.67, indicating that the current share price trades at a significant 43.8% discount. This raises the question of whether the market is overlooking Tenet’s long-term earnings potential.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Tenet Healthcare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 927 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

If you would rather chart your own path or want to interpret the numbers differently, you can build a personalized view of Tenet Healthcare in just a few minutes, Do it your way

A great starting point for your Tenet Healthcare research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Strengthen your portfolio by seeking out new opportunities and staying ahead of the curve with the Simply Wall Street Screener. You do not want to miss out on the next potential winner. Start exploring now and catch promising trends before everyone else does.

Uncover companies poised for explosive growth with these 3579 penny stocks with strong financials, where financial health meets high-return potential in overlooked market niches.

Power up your investment strategy by tapping into the future of technology with these 25 AI penny stocks, connecting you to stocks leading innovation powered by artificial intelligence.

Collect consistent income opportunities by evaluating 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 15 dividend stocks with yields > 3% offering yields above 3%, perfect for building steady, long-term returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include THC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com